This Week: MAPS’s second Phase 3 study of MDMA-AT for PTSD is on schedule Australia’s national science agency starts work on medicinal psychedelics ‘Death spiral financings’ arrive to the psychedelics space Psychedelics at Davos and more… MAPS’ Phase 3 MDMA Trial Is On Schedule MAPS’ second Phase 3 trial of MDMA-assisted therapy (MDMA-AT) for PTSD is right on schedule, according to the non-profit.


Previous articlePT320 – Anne Philippi – The New Health Club, Intergenerational Trauma, and Psychedelics in the Workplace
Next articlePT321 – Lyle Maxson – Virtual Reality, Biofeedback, and Digital Therapeutics: The Future of Mental Health